Related Experiment Video
Updated: Aug 13, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
Ruixian Xing1, Apeng Yang2, Juan Huang3
1Beijing Tiantan Hospital Beijing, Beijing China.
Blood Cancer Discovery
|August 11, 2026
Summary
Glofitamab shows high response rates in relapsed or refractory CNS lymphoma (R/R CNSL). This therapy offers a promising new option for patients with limited treatment choices.
Area of Science:
- Oncology
- Hematology
- Clinical Trials
Background:
- Relapsed or refractory central nervous system lymphoma (R/R CNSL) presents significant therapeutic challenges.
- Limited effective treatment options exist for patients with R/R CNSL.
Purpose of the Study:
- To evaluate the efficacy and safety of glofitamab in patients with R/R CNSL.
- To assess response rates, progression-free survival, and toxicity profiles of glofitamab therapy.
Main Methods:
- Multicenter retrospective study of 84 R/R CNSL patients.
- Analysis of glofitamab monotherapy and combination therapy outcomes.
- Evaluation of objective response rates (ORR), complete response rates (CRR), progression-free survival (PFS), and adverse events.
Main Results:
- High ORR (88-100%) and CRR (59-81%) observed for both primary CNS lymphoma (PCNSL) and secondary CNS lymphoma (SCNSL) with glofitamab.
- Median PFS of 19.5 months for PCNSL and 13.5 months for SCNSL.
- Manageable toxicity, with cytokine release syndrome in 40% (all grade 1-2) and ICANS in 8%.
Conclusions:
- Glofitamab-based therapy demonstrates substantial clinical activity in R/R CNSL.
- The treatment offers a promising therapeutic option with a manageable safety profile for this patient population.
